Mesenchymal Stem Cells for Treatment of Refractory Acute Graft-versus-host Disease
Mesenchymal Stem Cells From Third-party Donors for Treatment of Refractory Acute Graft-versus-host Disease
Sponsor: Guangdong Provincial People's Hospital
Listed as NCT01765634, this PHASE2 trial focuses on Acute Graft-versus-host Disease and remains ongoing. Sponsored by Guangdong Provincial People's Hospital, it has been updated 8 times since 2013, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Jul 2023 — Jul 2024 [monthly]
Unknown Status PHASE2
-
Jan 2021 — Jul 2023 [monthly]
Unknown Status PHASE2
-
Dec 2019 — Jan 2021 [monthly]
Unknown Status PHASE2
▶ Show 3 earlier versions
-
Jun 2018 — Dec 2019 [monthly]
Unknown Status PHASE2
-
Jun 2017 — Jun 2018 [monthly]
Unknown Status PHASE2
-
Jan 2017 — Jun 2017 [monthly]
Unknown Status PHASE2
First recorded
Jan 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Guangdong Provincial People's Hospital
- Guangzhou First People's Hospital
- Guangzhou General Hospital of Guangzhou Military Command
- Nanfang Hospital, Southern Medical University
- Peking University People's Hospital
- Southern Medical University, China
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- Sun Yat-sen University
- Third Affiliated Hospital, Sun Yat-Sen University
- Zhongshan People's Hospital, Guangdong, China
For direct contact, visit the study record on ClinicalTrials.gov .